AVIEW RT ACS

by Coreline Soft Co.  · Based in South Korea → — AI-powered precision for radiotherapy planning.
Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

AVIEW RT ACS by Coreline Soft is an advanced AI-based radiotherapy autocontouring system designed to enhance the efficiency and accuracy of radiation treatment planning. Utilizing deep learning technology, it automatically segments organs at risk (OARs) on CT images, significantly reducing the time and effort required for manual contouring. The system supports contouring for various anatomical regions, including the head and neck, breast, abdomen, and pelvis. By generating output in RT-DICOM format, AVIEW RT ACS seamlessly integrates into existing radiation treatment planning workflows, aiming to improve consistency and reduce variability among medical professionals. It is part of Coreline Soft’s broader AVIEW platform, which focuses on AI-driven diagnostic solutions for medical imaging.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Deep learning-based automatic organ segmentation
  • Supports head & neck, breast, abdomen, and pelvis contouring
  • Generates RT-DICOM format output
  • Reduces manual contouring time
  • Increases accuracy and consistency in contouring
  • Integrates with existing radiation treatment planning workflows (DICOM 3.0 support)
  • AI-powered medical image analysis
  • Automated contouring server for radiotherapy

Use Cases

  • Radiation treatment planning
  • Automated segmentation of organs at risk (OARs)
  • Breast radiotherapy planning
  • Head and neck radiotherapy planning
  • Abdomen and pelvis radiotherapy planning
  • Streamlining radiology workflows

What Physicians Need to Know

Key Capabilities
AVIEW RT ACS utilizes deep learning AI for automated organ segmentation and contour generation from CT scans, specifically for radiation oncology treatment planning. It can automatically contour up to 49 organs across head, neck, breast, abdomen, and pelvis regions, generating DICOM RT structures.
Clinical Utility
The tool significantly reduces treatment planning time and improves accuracy by providing initial organ contours. Studies show its accuracy is comparable to manual segmentation by experts (average Dice similarity coefficient of 0.90 for breast radiotherapy) and it helps maintain consistent contouring quality, protecting nearby organs during radiation.
Integration Options
AVIEW RT ACS automatically transmits segmented and contoured images to existing treatment planning systems, supporting DICOM RT. As part of the broader AVIEW platform, it offers flexible deployment options including cloud-based, hybrid, or local installations, and integrates with standard reading environments (PACS) and RIS. The platform is also validated against IHE and FHIR standards.
Compliance Status
AVIEW RT ACS received FDA 510(k) clearance on November 10, 2022. Coreline Soft, the developer, holds multiple FDA clearances for its AI algorithms.
User Experience
The system has demonstrated good user satisfaction, and the broader AVIEW platform emphasizes an optimized user interface (UI) and user experience (UX) with strengthened communication functions.
Implementation Complexity
The tool streamlines the contouring process by automating initial segmentation, requiring only minor final corrections from experts. Its flexible deployment modes (cloud, hybrid, local) offer adaptability to various clinical IT infrastructures.
Evidence Base
The performance of AVIEW RT ACS is supported by peer-reviewed publications demonstrating high correlation with manual contours and feasibility for breast radiotherapy planning. Coreline Soft's AVIEW platform has been used in over 2.5 million cases across 19 countries and is backed by more than 400 peer-reviewed publications.
Physician Tip

AVIEW RT ACS is a valuable AI assistant for radiation oncology, significantly reducing the manual effort and time spent on organ contouring for treatment planning. While it provides highly accurate initial contours, always review and make final adjustments to ensure patient-specific precision. Leverage its DICOM RT compatibility for seamless integration into your existing workflow to maximize efficiency and consistency in radiation therapy planning.

The AVIEW RT ACS is designed for integration into existing radiation treatment planning systems via DICOM RT. Its broader AVIEW platform supports various integration methods including PACS, RIS, AI marketplaces, and can function as a standalone application, with deployment options spanning cloud, hybrid, and on-premise solutions. Future developments aim for deeper integration with reporting platforms and adherence to IHE and FHIR standards for a comprehensive AI workflow.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor
DeploymentOn-premises, Cloud-based, Hybrid solution
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

AVIEW RT ACS received FDA 510(k) clearance on July 9, 2023. It is cleared as an AI-based radiotherapy autocontouring system for deep learning-based autosegmentation of organs on CT and generation of head and neck, breast, abdomen, and pelvis contouring in an RT-DICOM format.
Integrations
EHR Not specified
Specialties Oncology, Radiology

What the Web Says

AVIEW RT ACS is an AI-powered auto-segmentation system developed by Coreline Soft for radiotherapy planning. It uses deep learning to automatically contour organs-at-risk (OARs) and target volumes from CT scans, aiming to improve efficiency and consistency in treatment planning. The system has received FDA clearance and has shown promising results in studies, particularly for breast cancer radiotherapy.

Overall: Positive

Strengths

  • Reduces time spent on manual segmentation, allowing more focus on treatment planning.
  • Enhances consistency and quality of contouring, reducing variability among readers.
  • Accuracy similar to manual segmentation by experts.
  • Feasible and beneficial for breast radiotherapy planning.
  • Supports various anatomical sites including head & neck, breast, abdomen, and pelvis.
  • Integrates with current radiation treatment plan workflows (RT-DICOM format).

Limitations

  • One study noted a good correlation for most OARs and CTVs, but exceptions were the right coronary artery and left anterior descending artery.
  • Limited independent user reviews available outside of research studies and company information.
  • No specific negative feedback from Reddit, G2, or Capterra found for this particular product.

Based on reviews from: Coreline Soft (corelinesoft.com), AuntMinnie.com, X-ray Interpreter, YouTube

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AVIEW RT ACS

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

KBR
Coreline's AI-based oncology contouring device wins FDA 510(k) clearance
Coreline Soft's AVIEW RT ACS, an AI-based fully automatic contouring solution for oncology, received FDA 510(k) certification in November 2022. This approval allows the device to be marketed in the U.S. for segmenting organs to precisely target cancer cells during radiation therapy.
2022-11
AuntMinnie
FDA clears Coreline's AI-based radiotherapy autocontouring system
The U.S. Food and Drug Administration (FDA) cleared Coreline Soft's AView RT ACS, an AI-based radiotherapy autocontouring system, in July 2023. The system uses deep learning for autosegmentation of organs on CT scans for head and neck, breast, abdomen, and pelvis contouring in an RT-DICOM format.
2023-07
Business Wire
Coreline Soft Showcases Deep Learning AI Imaging Solutions 'AVIEW' at ECR 2024
Coreline Soft showcased its AVIEW product line, including AVIEW RT ACS, an AI-based fully automated contouring solution, at the European Congress of Radiology (ECR) 2024. The exhibition featured demonstrations of their AI medical imaging solutions for screening, diagnosis, treatment, and management.
2024-02
KBR
Coreline Soft partners with HealthCare Konnect to accelerate Swiss expansion
Coreline Soft completed pre-market notification for its AVIEW products, including AVIEW RT ACS, in Switzerland in August 2023, enabling expansion into the Swiss medical market. This partnership aims to broaden the reach of their AI-based medical imaging solutions.
2023-08
TMG Pulse
Singapore OKs Coreline Soft's AI imaging diagnosis solutions
Coreline Soft obtained medical device certifications from Singapore's Health Sciences Authority for several AI diagnostic support solutions, including AVIEW RT ACS, in December 2022. This approval is part of Coreline Soft's aggressive global expansion strategy.
2022-12
Coreline Soft
Coreline Soft Ranks Top 20 in FDA-Approved AI Medical Devices
Coreline Soft announced in January 2026 that it ranks among the top 20 in FDA-approved AI medical devices, with over 400 peer-reviewed publications related to medical AI. The company is expanding its U.S. patent portfolio and global presence.
2026-01
ResearchGate (International Journal of Radiation Oncology*Biology*Physics)
Experience of Implementing Deep Learningu2013Based Automatic Contouring in Breast Radiation Therapy Planning: Insights From Over 2000 Cases
A study published in February 2024 evaluated the performance of Coreline Soft's AVIEW RT ACS in deep learning-based automatic segmentation of organs at risk in breast cancer patients receiving radiation therapy. The study found a high correlation with manual contours, suggesting its feasibility and benefit for breast radiotherapy planning.
2024-02
ITN Online
Coreline Soft to Introduce Next-Generation AI Platform at RSNA 2025
Coreline Soft will introduce its AVIEW 2.0 AI platform at RSNA 2025, demonstrating how unified AI automation is transforming radiology workflows and elevating diagnostic precision. While not exclusively about AVIEW RT ACS, it highlights the company's broader AI platform development which includes such solutions.
2025-11

Videos

Product demos, reviews, and walkthroughs for AVIEW RT ACS.

View all on YouTube

Frequently Asked Questions

AVIEW RT ACS is designed to seamlessly integrate into the radiotherapy planning workflow by automatically segmenting organs at risk (OARs) and target volumes from CT scans. After a CT scan for treatment planning, data is transferred to AVIEW RT ACS, which then automatically contours the organs using deep learning AI. This segmented data is subsequently transmitted to the treatment planning system (TPS), allowing physicians to spend more time on treatment planning rather than manual contouring.
AVIEW RT ACS has received significant regulatory clearances, including FDA 510(k) clearance in the United States. Additionally, it holds certifications from various international bodies such as MFDS (Republic of Korea), PMDA (Japan), CE (Europe), TGA (Australia), HSA (Singapore), and HC (Canada). These clearances affirm its compliance with established medical device standards in multiple regions.
While specific details on AVIEW RT ACS's HIPAA compliance are not explicitly detailed in the provided information, as a medical AI solution operating in the U.S. healthcare market, it is expected to adhere to stringent patient data privacy and security regulations like HIPAA. Coreline Soft, the developer, operates within a regulatory landscape that mandates such compliance for medical devices handling protected health information. Generally, medical AI solutions implement security measures such as encryption, access controls, and secure data transfer protocols to protect patient data.
AVIEW RT ACS offers significant advantages by automating the time-consuming process of organ segmentation, thereby reducing radiotherapy preparation time and improving consistency. Studies have shown it can reduce the average contouring time while maintaining or increasing accuracy compared to manual methods. This automation helps reduce variability among readers and allows medical staff to focus more on complex treatment planning.
AVIEW RT ACS has demonstrated high accuracy, with studies showing a Dice similarity coefficient (DSC) of 0.80 or higher on all OARs and 0.70 or higher on all breast and local lymph node CTVs, with an average DSC of 0.90, indicating accuracy similar to expert manual segmentation. However, like all AI systems, its limitations generally include potential generalization issues beyond its training data and the necessity for continued human oversight. AI is intended to augment, not replace, physician judgment.
Specific pricing details for AVIEW RT ACS are not publicly available in the provided search results. Pricing for such specialized medical AI software is typically handled through direct negotiations with the vendor, Coreline Soft, and is often tailored to the specific needs and scale of the healthcare institution. It is likely based on a B2B model, potentially involving licensing fees, subscription models, or per-use charges, which would be discussed during a direct inquiry or demo request.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Coreline Soft

A View LCS
Coreline Soft Co.
Cardiology AI
AVIEW LCS by Coreline Soft is an FDA-cleared AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan.
Contact for quote
AVIEW
Coreline Soft Co.
Cardiology AI
Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows.
Subscription; one-off payment
AVIEW CAC
Coreline Soft Co.
Cardiology AI
AI-powered software for automated coronary artery calcium analysis from CT scans, providing quantitative results and risk assessment to aid in early detection and management of coronary artery disease.
AVIEW LCS
Coreline Soft Co.
Cardiology AI
Coreline Soft's AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules. The AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and streamlining radiology workflows.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.